Twist Bioscience Corp (TWST)

Overview News Price History Option Chain Discussions Forecast

Twist Bioscience Corp stock is currently priced at $27.95, with a 24-hour trading volume of 1.07M. It has seen a -1.45% decreased in the last 24 hours and a -17.33% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $28.47 pivot point. If it approaches the $27.91 support level, significant changes may occur.

Twist Bioscience Corp Stock (TWST) Financials Data

Twist Bioscience Corp (TWST) Revenue 2024

TWST reported a revenue (TTM) of $262.36 million for the quarter ending December 31, 2023, a +21.58% rise year-over-year.

Twist Bioscience Corp (TWST) Net Income 2024

TWST net income (TTM) was -$205.80 million for the quarter ending December 31, 2023, a +3.89% increase year-over-year.

Twist Bioscience Corp (TWST) Cash Flow 2024

TWST recorded a free cash flow (TTM) of -$128.84 million for the quarter ending December 31, 2023, a +44.63% increase year-over-year.

Twist Bioscience Corp (TWST) Earnings per Share 2024

TWST earnings per share (TTM) was -$3.61 for the quarter ending December 31, 2023, a +6.48% growth year-over-year.

Twist Bioscience Corp Stock (TWST) Latest News

Analyst Scoreboard: 5 Ratings For Twist Bioscience

Benzinga

Cathie Wood's Ark Continues Tesla Stock Buying Spree, Acquires Over $14M Worth Of Shares Amid Dip

Benzinga

Cathie Wood's Ark Invest Offloads $6.9M Worth of Coinbase, Robinhood Shares Each Amid Searing Bitcoin Rally — Nvidia Stock Also Shed

Benzinga

Cathie Wood Trims Nvidia, Shopify Stakes To Pump Whopping $40M Into Pinterest Despite Q4 Revenue Miss

Benzinga

Cathie Wood's Ark Invest Sheds $2.8M Worth Of Nvidia Shares Amid AI Hype, Picks Up Robinhood Stock Worth $1.3M

Benzinga

4 Analysts Have This To Say About Twist Bioscience

Benzinga

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company was founded in 2013 and is headquartered in San Francisco, California.

Upgrade	Goldman: Neutral → Buy	Jan-17-24
Initiated	Berenberg: Buy	Sep-27-23
Initiated	Scotiabank: Sector Outperform	Jan-05-23
Upgrade	Evercore ISI: In-line → Outperform	Jan-03-23
Resumed	Cowen: Outperform	Mar-02-22
Resumed	Cowen: Outperform	Oct-15-21
Initiated	William Blair: Outperform	Jun-29-21
Initiated	Goldman: Neutral	Jun-04-21
Initiated	Piper Sandler: Overweight	Apr-12-21
Downgrade	JP Morgan: Neutral → Underweight	Feb-05-21
Downgrade	Evercore ISI: Outperform → In-line	Jan-04-21
Initiated	SVB Leerink: Mkt Perform	Oct-20-20
Initiated	Evercore ISI: Outperform	May-31-19
Initiated	JP Morgan: Neutral	Nov-26-18